Dosing Considerations for Obese Patients Receiving Cancer Chemotherapeutic Agents

No abstract is available for this paper.

• Publication year

  2013

• Venue

  The Annals of Pharmacotherapy

• Publication date

  2013-11-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1060028013509789PMID 24259627
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Weight Drives Caspofungin Pharmacokinetic Variability in Overweight and Obese People: Fractal Power Signatures beyond Two-Thirds or Three-Fourths

  2013cited by this paper
• Drug Dosing Based on Weight and Body Surface Area: Mathematical Assumptions and Limitations in Obese Adults

  2012cited by this paper
• Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.

  2012influential reference
• Evaluation of chemotherapy-induced severe myelosuppression incidence in obese patients with capped dosing.

  2011cited by this paper
• Fractal Geometry and the Pharmacometrics of Micafungin in Overweight, Obese, and Extremely Obese People

  2011cited by this paper
• Protein Binding: Do We Ever Learn?

  2011cited by this paper
• Ethambutol Pharmacokinetic Variability Is Linked to Body Mass in Overweight, Obese, and Extremely Obese People

  2011cited by this paper
• Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass.

  2010cited by this paper
• Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice.

  2010cited by this paper
• Estimating the glomerular filtration rate in obese adult patients for drug dosing.

  2010cited by this paper
• Estimation of creatinine clearance in morbidly obese patients.

  2009cited by this paper
• Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study

  2009cited by this paper
• A Universal Formula Based on Cystatin C to Perform Individual Dosing of Carboplatin in Normal Weight, Underweight, and Obese Patients

  2009cited by this paper
• Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

  2009cited by this paper
• Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study.

  2008influential reference
• PHARMACOKINETICS OF DOXORUBICIN AND ETOPOSIDE IN A MORBIDLY OBESE PEDIATRIC PATIENT

  2007cited by this paper
• Epidemiology and pathophysiology of obesity as cause of cancer.

  2007cited by this paper
• Impact of body mass index on treatment outcomes in endometrial cancer patients receiving doxorubicin and cisplatin: a Gynecologic Oncology Group study.

  2007cited by this paper
• Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.

  2007influential reference
• Prospective evaluation of carboplatin AUC dosing in patients with a BMI ≥27 or Cachexia

  2006cited by this paper
• Prevalence of overweight and obesity in the United States, 1999-2004.

  2006cited by this paper
• Chemotherapy dose intensity and quality cancer care.

  2006cited by this paper
• Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.

  2005cited by this paper
• Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index.

  2005cited by this paper
• Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients

  2004cited by this paper
• Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.

  2004cited by this paper
• Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution

  2004cited by this paper
• Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.

  2004influential reference
• Glimepiride Pharmacokinetics in Obese Versus Non-Obese Diabetic Patients

  2004cited by this paper
• Influence of body mass index on outcomes and treatment‐related toxicity in patients with colon carcinoma

  2003cited by this paper
• Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma

  2002cited by this paper
• Are medical oncologists biased in their treatment of the large woman with breast cancer?

  2001cited by this paper
• Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation.

  1998cited by this paper
• Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541.

  1996cited by this paper
• Epirubicin as a single agent therapy for the treatment of breast cancer — A pharmacokinetic and clinical study

  1992cited by this paper
• Disposition of high‐dose methotrexate in an obese cancer patient

  1991cited by this paper
• Doxorubicin clearance in the obese.

  1988cited by this paper

• Initial chemotherapy dose reductions and subsequent treatment delivery in stage I–IIIA breast cancer

  2026cites this paper
• Dosing chemotherapy in children with obesity: literature review and evaluation of local practices

  2025cites this paper
• Correlation analysis of pharmacokinetic parameters of docetaxel AUC and adverse reactions in breast cancer patients

  2025cites this paper
• Overweight and Obesity are Associated with Poorer Survival Among Patients with Advanced Non-Small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

  2023cites this paper
• Pharmacogenetics and Adverse Events in the Use of Fluoropyrimidine in a Cohort of Cancer Patients on Standard of Care Treatment in Zimbabwe

  2023cites this paper
• Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials

  2023cites this paper
• Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper

  2021cites this paper
• The influence of nutrition on clinical outcomes in children with cancer

  2020cites this paper
• Successful Treatment of Delayed Methotrexate Clearance Using Glucarpidase Dosed on Ideal Body Weight in Obese Patients

  2020cites this paper
• Comparison of Body Size, Morphomics, and Kidney Function as Covariates of High‐Dose Methotrexate Clearance in Obese Adults with Primary Central Nervous System Lymphoma

  2020cites this paper
• The relevance of nutrition to pediatric oncology: A cancer control perspective

  2020cites this paper
• Mechanisms by Which Obesity Impacts Survival from Acute Lymphoblastic Leukemia.

  2019cites this paper
• Heterogeneity of fatty acid metabolism in breast cancer cells underlies differential sensitivity to palmitate‐induced apoptosis

  2018cites this paper
• Individualizing Dosage Regimens of Antineoplastic Agents

  2017cites this paper
• Considerations for dosing immunoglobulin in obese patients

  2017cites this paper
• A high BMI is a risk factor in younger patients with de novo acute myelogenous leukemia

  2016cites this paper
• 20. A growing risk in a growing population: obesity's impact on leukemia incidence and survival

  2016cites this paper
• Clinical Impact of Abdominal Fat Distribution on Prognosis After Esophagectomy for Esophageal Squamous Cell Carcinoma

  2016cites this paper
• Elucidating the effects of metabolic state on nanoparticle distribution in mice and in vitro uptake

  2016cites this paper
• Evaluation of Patient Characteristics, Indications, and Effectiveness of Home Parenteral Nutrition (HPN) Therapy in Obese Adult Patients

  2015cites this paper
• Cancer-Associated Venous Thromboembolic Disease, Version 1.2015.

  2015cites this paper
• The impact of insulin on chemotherapeutic sensitivity to 5-fluorouracil in gastric cancer cell lines SGC7901, MKN45 and MKN28

  2015cites this paper
• Drug disposition in obesity: toward evidence-based dosing.

  2015cites this paper
• Pediatric Obesity: Pharmacokinetics and Implications for Drug Dosing.

  2015cites this paper
• [Obesity and lung cancer: incidence and repercussions on epidemiology, pathology and treatments].

  2015cites this paper
• The Influence Of Obesity On Results Of AT (Doxorubicin Plus Docetaxel) Neoadjuvant Chemotherapy In Locally Advanced Breast Cancer Patients.

  2015cites this paper
• Therapeutic immunoglobulin should be dosed by clinical outcome rather than by body weight in obese patients

  2015cites this paper
• Obesity and Resistance to Cancer Chemotherapy: Interacting Roles of Inflammation and Metabolic Dysregulation

  2014cites this paper